Physician profile
Bipinkumar Amin
NPI 1568415628
$291,686.29
in general payments reported to CMS, 2019-2025
81 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $13K · 2021: $39K · 2022: $60K · 2023: $32K · 2024: $55K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $27K · Travel and Lodging: $21K · Food and Beverage: $7,752 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,202.50 |
| Consulting Fee | $26,803.00 |
| Travel and Lodging | $21,082.30 |
| Food and Beverage | $7,751.73 |
| Education | $324.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $112,726.81 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $79,670.50 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $13,416.56 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Genzyme Corporation | $13,312.26 | 2020-2025 | |
| Geron Corporation | $12,834.42 | 2024-2025 | Rytelo |
| Celgene Corporation | $10,904.58 | 2019-2025 | Reblozyl, Inrebic, Opdualag |
| Glaxosmithkline, LLC. | $8,993.06 | 2019-2025 | Ojjaara, Shingrix |
| Ipsen Biopharmaceuticals, INC | $6,927.70 | 2019-2020 | |
| Beigene USA, INC. | $3,746.53 | 2021-2025 | Brukinsa |
| Seagen INC. | $3,355.00 | 2020-2023 | Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $3,187.34 | 2019-2025 | Opdivo |
| Exelixis INC. | $2,966.81 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $2,298.97 | 2020-2021 | |
| Astellas Pharma Global Development | $2,015.64 | 2019-2021 | |
| Incyte Corporation | $1,981.31 | 2021-2024 | Monjuvi, Pemazyre, Jakafi |
Show all 78 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipinkumar Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.